1. J Hematol Oncol. 2015 Feb 25;8:16. doi: 10.1186/s13045-015-0113-9.

Cancer stem cells in basic science and in translational oncology: can we 
translate into clinical application?

Schulenburg A(1)(2)(3), Blatt K(4), Cerny-Reiterer S(5)(6), Sadovnik I(7), 
Herrmann H(8)(9), Marian B(10)(11), Grunt TW(12)(13), Zielinski CC(14)(15), 
Valent P(16)(17).

Author information:
(1)Bone Marrow Transplantation Unit, Department of Internal Medicine I, Medical 
University of Vienna, Währinger Gürtel 18-20, Vienna, A-1090, Wien, Austria. 
axel.schulenburg@meduniwien.ac.at.
(2)Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Spitalgasse 
23, Vienna, 1090, Wien, Austria. axel.schulenburg@meduniwien.ac.at.
(3)Department of Medicine I, Stem Cell Transplantation Unit, Medical University 
of Vienna, Waehringer Guertel 18-20, A-1090, Wien, Austria. 
axel.schulenburg@meduniwien.ac.at.
(4)Department of Medicine I, Division of Hematology and Hemostaseology, Medical 
University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Wien, Austria. 
katharina.blatt@meduniwien.ac.at.
(5)Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Spitalgasse 
23, Vienna, 1090, Wien, Austria. sabine.cerny-reiterer@meduniwien.ac.at.
(6)Department of Medicine I, Division of Hematology and Hemostaseology, Medical 
University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Wien, Austria. 
sabine.cerny-reiterer@meduniwien.ac.at.
(7)Department of Medicine I, Division of Hematology and Hemostaseology, Medical 
University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Wien, Austria. 
irina.sadovnik@meduniwien.ac.at.
(8)Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Spitalgasse 
23, Vienna, 1090, Wien, Austria. harald.herrmann@meduniwien.ac.at.
(9)Department of Radiation Therapy, Medical University of Vienna, Spitalgasse 
23, Vienna, 1090, Wien, Austria. harald.herrmann@meduniwien.ac.at.
(10)Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Spitalgasse 
23, Vienna, 1090, Wien, Austria. brigitte.marian@meduniwien.ac.at.
(11)Department of Medicine I, Institute for Cancer Research, Medical University 
of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Wien, Austria. 
brigitte.marian@meduniwien.ac.at.
(12)Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Spitalgasse 
23, Vienna, 1090, Wien, Austria. thomas.grunt@meduniwien.ac.at.
(13)Department of Medicine I, Division of Clinical Oncology, Medical University 
of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Wien, Austria. 
thomas.grunt@meduniwien.ac.at.
(14)Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Spitalgasse 
23, Vienna, 1090, Wien, Austria. christoph.zielinski@meduniwien.ac.at.
(15)Department of Medicine I, Division of Clinical Oncology, Medical University 
of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Wien, Austria. 
christoph.zielinski@meduniwien.ac.at.
(16)Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Spitalgasse 
23, Vienna, 1090, Wien, Austria. peter.valent@meduniwien.ac.at.
(17)Department of Medicine I, Division of Hematology and Hemostaseology, Medical 
University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Wien, Austria. 
peter.valent@meduniwien.ac.at.

Since their description and identification in leukemias and solid tumors, cancer 
stem cells (CSC) have been the subject of intensive research in translational 
oncology. Indeed, recent advances have led to the identification of CSC markers, 
CSC targets, and the preclinical and clinical evaluation of the CSC-eradicating 
(curative) potential of various drugs. However, although diverse CSC markers and 
targets have been identified, several questions remain, such as the origin and 
evolution of CSC, mechanisms underlying resistance of CSC against various 
targeted drugs, and the biochemical basis and function of stroma cell-CSC 
interactions in the so-called 'stem cell niche.' Additional aspects that have to 
be taken into account when considering CSC elimination as primary treatment-goal 
are the genomic plasticity and extensive subclone formation of CSC. Notably, 
various cell fractions with different combinations of molecular aberrations and 
varying proliferative potential may display CSC function in a given neoplasm, 
and the related molecular complexity of the genome in CSC subsets is considered 
to contribute essentially to disease evolution and acquired drug resistance. In 
the current article, we discuss new developments in the field of CSC research 
and whether these new concepts can be exploited in clinical practice in the 
future.

DOI: 10.1186/s13045-015-0113-9
PMCID: PMC4345016
PMID: 25886184 [Indexed for MEDLINE]